Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 81, Issue 5, pp 949–955 | Cite as

Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study

  • Ryusei Matsuyama
  • Daisuke Morioka
  • Ryutaro Mori
  • Seigo Hiratani
  • Yasuhiro Yabushita
  • Yohei Ota
  • Takafumi Kumamoto
  • Koichi Taniguchi
  • Itaru Endo
Original Article

Abstract

Background

NCCN and Japanese clinical guidelines for the treatment of biliary tract cancer (BTC) addressed gemcitabine–cisplatin combination (GC) as first-line chemotherapy for patients with advanced BTC ineligible for surgery in 2013. However, gemcitabine–S1 combination therapy (GS) has been widely used as first-line treatment in Japan because Japanese social insurance coverage of S-1 for BTC was approved prior to that of cisplatin.

Aim

To elucidate the efficacy and tolerability of GC as second-line chemotherapy for patients with unresectable BTC after failure of GS.

Patients and methods

Between September 2008 and August 2011, patients with unresectable BTC who provided informed consent and received GC comprising gemcitabine at 1000 mg/m2 and cisplatin at 20 mg/m2 given on days 1 and 8 in a 3-week cycle after failure of GS were included in the present study. Clinical data from these patients were collected prospectively. Primary endpoints were overall survival and time to progression (TTP). Secondary endpoints were response and tolerability.

Results

Twenty-seven patients were analyzed. Median survival time (MST) and TTP from the beginning of second-line treatment were 6.5 and 3.3 months, respectively, whereas MST from the commencement of first-line therapy was 12.06 months. One patient showed partial response, 16 had stable disease and 10 experienced disease progression. As a result, disease control rate was 63.0%. In total, 119 courses (median, 4; range, 1–15) were administered. Discontinuation of GC due to drug toxicities was not observed.

Conclusion

Although some issues remain to be clarified, mainly due to the small sample size, this single-institution experience with GC as second-line treatment after failure of GS showed acceptable outcomes and good tolerability.

Keywords

Biliary tract cancer Gemcitabine Cisplatin S-1 Refractory 

Notes

Funding

No funding was received for this research.

Compliance with ethical standards

Conflict of interest

R. Matsuyama, D. Morioka, R. Mori, S. Hiratani, Y. Yabushita, Y. Ota, T. Kumamoto, K. Taniguchi and I. Endo declare they have no conflict of interest to disclose.

Ethical approval

This study was conducted in accordance with the Helsinki Declaration and Good Clinical Practices and was approved by the institutional review board. The study has been registered with UMIN Clinical Trials Registry (no.: UMIN000007571).

Informed consent

We obtained written informed consent from all patients prior to participation.

References

  1. 1.
    Gores GJ (2003) Cholangiocarcinoma: current concepts and insight. Hepatology 37:961–969CrossRefPubMedGoogle Scholar
  2. 2.
    Rajagopalan V, Daines WP, Grossbard ML et al (2004) Gallbladder and biliary tract carcinoma: a comprehensive up date, Part 1. Oncology 18:889–896PubMedGoogle Scholar
  3. 3.
    Matsuda T, Marugame T (2007) International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from cancer incidence in five continents. Jpn J Clin Oncol 37:74–75CrossRefPubMedGoogle Scholar
  4. 4.
    Randi G, Malvezzi M, Levi F et al (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146–159CrossRefPubMedGoogle Scholar
  5. 5.
    Leonard GD, O’Reilly EM (2005) Biliary tract cancer: current concepts and controversies. Expert Opin Pharmacother 6:211–223CrossRefPubMedGoogle Scholar
  6. 6.
    Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Eng J Med 362:1273–1281CrossRefGoogle Scholar
  8. 8.
    Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in japan. Br J Cancer 103:469–474CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Committee for Treatment Guideline for biliary tract cancer, Japanese Society for Hepato-Bilary-Pancreatic Surgery (2013) Treatment guideline for biliary tract cancer 2013, 2nd edn. Igakutosho shuppan, TokyoGoogle Scholar
  10. 10.
    Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855CrossRefPubMedGoogle Scholar
  11. 11.
    Sasaki T, Isayama H, Nakai Y et al (2010) Multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101–1107CrossRefPubMedGoogle Scholar
  12. 12.
    Kanai M, Yoshimura K, Tsumura T et al (2011) A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67:1429–1434CrossRefPubMedGoogle Scholar
  13. 13.
    Sasaki T, Isayama H, Nakai Y et al (2011) Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 29:1488–1489CrossRefPubMedGoogle Scholar
  14. 14.
    Sasaki T, Isayama H, Nakai Y et al (2011) Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 67:847–853CrossRefPubMedGoogle Scholar
  15. 15.
    Sasaki T, Isayama H, Takahara N et al (2013) A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy 59:106–111CrossRefPubMedGoogle Scholar
  16. 16.
    Paule B, Herelle MO, Rage E et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105–110CrossRefPubMedGoogle Scholar
  17. 17.
    Pino MS, Milella M, Gelibter A et al (2009) Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancer. Oncology 76:254–261CrossRefPubMedGoogle Scholar
  18. 18.
    Lee S, Oh SY, Kim BG et al (2009) Second line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 32:348–352CrossRefPubMedGoogle Scholar
  19. 19.
    Oh SY, Jeong CY, Hong SC et al (2011) Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 29:1066–1072CrossRefPubMedGoogle Scholar
  20. 20.
    Therasse P, Arbuck SG, Einsenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  21. 21.
    Stallard N (2012) Optimal sample sizes for phase II and pilot studies. Stat Med 31:1031–1042CrossRefPubMedGoogle Scholar
  22. 22.
    Sasaki T, Isayama H, Nakai Y et al (2013) A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 71:973–979CrossRefPubMedGoogle Scholar
  23. 23.
    Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Cin Oncol 23:2332–2338CrossRefGoogle Scholar
  24. 24.
    Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/ metastatic biliary tract carcinoma. Cancer 104:2753–2758CrossRefPubMedGoogle Scholar
  25. 25.
    Riechelmann RP, Townsley CA, Chin SN et al (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307–1312CrossRefPubMedGoogle Scholar
  26. 26.
    Iqbal S, Rankin C, Lenz HJ et al (2011) A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 68:1595–1602CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a north central cancer treatment group phase II trial. Cancer 103:111–118CrossRefPubMedGoogle Scholar
  28. 28.
    Aranyl I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464CrossRefGoogle Scholar
  29. 29.
    Kyrochristos ID, Glantzounis GK, Ziogas DE et al (2017) From clinical standards to translating next-generation sequencing research into patient care improvement of hepatobiliary and pancreatic cancers. Int J Mol Sci.  https://doi.org/10.3390/ijms18010180 PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Gastroenterological SurgeryYokohama City University Graduate School of MedicineYokohamaJapan

Personalised recommendations